These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1905621)

  • 1. Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects.
    Price DE; Alani SM; Wales JK
    Diabetes Care; 1991 May; 14(5):411-3. PubMed ID: 1905621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
    Price DE; Airey CM; Alani SM; Wales JK
    Diabetes; 1988 Jul; 37(7):969-73. PubMed ID: 3133261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P
    J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
    Ziegler D; Mayer P; Rathmann W; Gries FA
    Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
    Boland OM; Blackwell CC; Clarke BF; Ewing DJ
    Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
    Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
    Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aldose reductase inhibition with ponalrestat on the width of the capillary basement membrane in diabetes mellitus.
    Ramirez LC; Arauz C; Pruneda L; Hammon K; Rosenstock J; Raskin P
    Diabetes Res Clin Pract; 1991 Feb; 11(2):73-80. PubMed ID: 1902410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
    Judzewitsch RG; Jaspan JB; Polonsky KS; Weinberg CR; Halter JB; Halar E; Pfeifer MA; Vukadinovic C; Bernstein L; Schneider M; Liang KY; Gabbay KH; Rubenstein AH; Porte D
    N Engl J Med; 1983 Jan; 308(3):119-25. PubMed ID: 6401351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats: effects of extracellular glucose concentration and of aldose reductase inhibition.
    Carrington AL; Ettlinger CB; Tomlinson DR
    J Diabetes Complications; 1994; 8(1):33-9. PubMed ID: 8167385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.
    Cameron NE; Cotter MA
    Br J Pharmacol; 1992 Dec; 107(4):939-44. PubMed ID: 1467842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
    Florkowski CM; Rowe BR; Nightingale S; Harvey TC; Barnett AH
    Diabetes; 1991 Jan; 40(1):129-33. PubMed ID: 1901808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
    Cameron NE; Cotter MA; Robertson S
    Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
    Ranganathan S; Krempf M; Feraille E; Charbonnel B
    Diabete Metab; 1993; 19(2):257-61. PubMed ID: 8339858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve.
    Calcutt NA; Mizisin AP; Kalichman MW
    Eur J Pharmacol; 1994 Jan; 251(1):27-33. PubMed ID: 8137868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
    Pfeifer MA
    Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.
    Pedersen MM; Christiansen JS; Mogensen CE
    Diabetes; 1991 May; 40(5):527-31. PubMed ID: 1902426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
    Umeda F; Noda K; Hashimoto T; Yamashita T; Nawata H
    Diabetes Res; 1989 Nov; 12(3):125-9. PubMed ID: 2561396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
    Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.